Clinical study of Shugan Jianpi Huazhi Decoction combined with Tongluo Yanggan application in the treatment of non-alcoholic fatty liver disease

Phase 1

Recruiting

• Conditions: non-alcoholic fatty liver disease

• Registration Number: ITMCTR2022000098
• Lead Sponsor: Guang'anmen Hospital, China Academy of Chinese Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 20 February 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Meet the diagnostic criteria of non-alcoholic fatty liver disease;
2. Meet the diagnostic criteria of Tanzhuo Neizu;
3. Between the ages of 18 and 65, regardless of gender;
4. Willing to participate in the research and sign the informed consent.

Exclusion Criteria

1. Patients with hepatitis B, C and other liver diseases;
2. Patients with alcoholic liver disease, autoimmune liver disease, drug liver disease, toxic hepatitis, hepatic malignant tumor, occult hepatitis, liver disease of unknown cause;
3. Pregnant or lactation women, allergic constitution;
4. Patients with mental abnormalities who cannot cooperate with this study;
5. Patients complicated with serious diseases of the heart, brain, lung, kidney, hematopoietic and immune systems;
6. Other conditions considered unsuitable for inclusion by the researcher.

Study & Design

• Study Type: Interventional study
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
blood uric acid;liver ultrasound;LSM;blood sugar;liver function;lipid profile;CAP;

Secondary Outcome Measures

Name	Time	Method
FIB-4 Index;Four items of liver fibrosis;TCM symptoms;APRI Index;